Protocol Ledger

NCT05180734 · Phase III · ACTIVE NOT RECRUITING

PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric Cancer

Interventional Phase III clinical trial protocol NCT05180734 sponsored by Shanghai Junshi Bioscience Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-10 Enrollment: 878 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05180734
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)878 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05180734
Protocol FieldVerified Registry Value
NCT IdentifierNCT05180734
Consolidated Lead SponsorShanghai Junshi Bioscience Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment878 participants (ACTUAL)
Registered Start Date2022-02-10
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI